AMED Stock Cash Flow Statements

Amedisys Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Amedisys Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31

cash flows from operating activities:
net income	7,302,000	7,760,000	7,930,000	7,110,000	6,136,000	5,186,000	9,177,779	4,221	3,363	2,381	1,514	1,149
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	1,988,000	2,123,000	1,530,000	1,332,000	1,092,000	1,229,000					762	740
non-cash compensation
amortization and impairment of operating lease right of use assets
gain on disposal of property and equipment
gain on equity method investment
gain on termination of joint venture
deferred income taxes	6,971,000	-305,000	287,000	472,000	2,793,000	1,052,000	3,149,673	1,327	1,764	1,327	869	660
equity in earnings from equity method investments
amortization of deferred debt issuance costs
return on equity method investments
impairment
changes in operating assets and liabilities:
patient accounts receivable
other current assets
operating lease right of use assets
other assets
accounts payable
accrued expenses
other long-term obligations
operating lease liabilities
net cash from operating activities	14,547,000	15,598,000	2,767,000	10,628,000	5,140,000	8,516,000	16,045,267	9,733	5,769	3,881	6,755	5,383
capex	0	-3,747,000	-6,173,000	-5,518,000	-1,661,000	-1,686,000	-1,883,375	-625	-1,044	-122	-325	-298
free cash flows	14,547,000	11,851,000	-3,406,000	5,110,000	3,479,000	6,830,000	14,161,892	9,108	4,725	3,759	6,430	5,085
cash flows from investing activities:
proceeds from the sale of deferred compensation plan assets
proceeds from the sale of property and equipment
purchases of property and equipment
investments in technology assets
investment in equity method investee
net cash from investing activities	23,796,000	-125,212,000	-10,139,000	-21,146,000	63,809,000	-6,255,000	-22,588,233	-14,767	-1,278	-6,426	-325	-298
cash flows from financing activities:
proceeds from issuance of stock upon exercise of stock options
shares withheld to pay taxes on non-cash compensation
noncontrolling interest contributions
noncontrolling interest distributions
principal payments of long-term obligations
debt issuance costs
net cash from financing activities	-9,861,000	58,300,000	518,000	-244,000	-1,999,000	68,641,000	-951,593	-407	15,224	-192	-1,970	-1,605
net increase in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash at beginning of period
cash, cash equivalents and restricted cash at end of period
supplemental disclosures of cash flow information:
cash paid for interest
cash paid for income taxes, net of refunds received
cash paid for operating lease liabilities
cash paid for finance lease liabilities
supplemental disclosures of non-cash activity:
right of use assets obtained in exchange for operating lease liabilities
right of use assets obtained in exchange for finance lease liabilities
reductions to right of use assets resulting from reductions to operating lease liabilities
reductions to right of use assets resulting from reductions to finance lease liabilities
(gain) loss on disposal of property and equipment
proceeds from the issuance of stock upon exercise of stock options
net decrease in cash, cash equivalents and restricted cash
home health:
medicare
non-medicare - episodic-based
non-medicare - non-episodic based
hospice:
non-medicare
high acuity care
gain on deconsolidation of joint venture
loss on personal care divestiture
merger termination fee
equity in (earnings) income from equity method investments
changes in operating assets and liabilities, net of impact of acquisitions:
purchase of cost method investment
return of investment
proceeds from personal care divestiture
acquisitions of businesses, net of cash acquired
proceeds from issuance of stock to employee stock purchase plan	564,000	247,000
proceeds from sale of noncontrolling interest
purchase of noncontrolling interest
proceeds from borrowings under revolving line of credit
repayments of borrowings under revolving line of credit
purchase of company stock
payment of accrued contingent consideration
cash paid for infinity zpic interest
accrued contingent consideration
noncontrolling interest contribution
investments in equity method investees
proceeds from issuance of stock under employee stock purchase plan
gain on equity method investments
investment impairment
proceeds from borrowings under term loan
provider relief fund advance
loss on disposal of property and equipment
(gain) loss on equity method investments
write-off of other comprehensive income
equity in loss (earnings) from equity method investments
amortization of deferred debt issuance costs/debt discount
impairment charge
proceeds from sale of equity method investment
other investments
non-cash 401(k) employer match
asset impairment charge
purchase of investment
assets
current assets:
cash and cash equivalents
total current assets
property and equipment
total assets
liabilities
current liabilities:
payroll and employee benefits
current portion of long-term obligations
total current liabilities
total liabilities
proceeds from sale of deferred compensation plan assets
proceeds from sale of property and equipment	29,000	106,000	-41,000	115,000	53,000	26,000	22,991	9
noncontrolling interest distribution
return on equity investment
loss on sale of equity method investment
non-controlling interest distribution
repurchase of noncontrolling interest
supplemental disclosures of non-cash financing activity:
note payable issued for software licenses
401(k) employer match
shares withheld upon stock vesting
supplemental disclosures of non-cash financing activities:
net increase in cash and cash equivalents	28,481,000				-2,952,000	70,902,000	-7,494,559	-5,441	19,715	-2,737	4,460	3,480
cash and cash equivalents at beginning of period		0	0	89,679,000		0	29,749,221	29,779		0	0	4,861
cash and cash equivalents at end of period		-51,313,000	-6,854,000	78,917,000		70,902,000	22,254,662	24,338		-2,737	4,460	8,341
write off of deferred debt issuance costs
net decrease in cash and cash equivalents			-6,854,000	-10,762,000
write-off of investment
tax benefit from stock options exercised and restricted stock vesting
assets contributed to equity investment
capital leases
proceeds from issuance of stock upon exercise of stock options and warrants	1,183,000	1,742,000	796,000	306,000		1,385,000	1,650,181	819		184	60	453
securities class action lawsuit settlement accrual
benefit from doubtful accounts
gain on sale of care centers
write off of deferred debt issuance costs/debt discount
purchases of deferred compensation plan assets
purchase of investments
proceeds from sale of investment
proceeds from disposition of care centers
proceeds from revolving line of credit	10,000,000
repayments of revolving line of credit
proceeds from issuance of long-term obligations
sale of non-controlling interest
equity in income from equity method investments
u.s. department of justice settlement
supplemental disclosures of non-cash financing and investing activities:
(sale) acquisition of non-controlling interests
proceeds from dispositions of care centers
equity in earnings of equity investments
u.s. department of justice settlement accrual
proceeds from deferred compensation plan assets
tax benefit from stock option exercises	324,000	1,955,000	688,000	341,000	198,000	1,185,000	1,049,120	880	417	0	0	9
goodwill and other intangibles impairment charge
purchases of investments
net cash (used in) investing activities
notes payable issued for software licenses
other intangibles impairment charge
proceeds from dispositions of care centers, net of cash sold
acquired non-controlling interests
payment of deferred financing fees
notes payable issued for/assumed in acquisitions
write off of intangible assets
acquisitions of reacquired franchise rights
equity in earnings from equity investments
outstanding checks in excess of bank balance
net cash (used in) financing activities
equity in earnings of unconsolidated joint ventures
notes payable issued for acquisitions			500,000	2,900,000	0
gain on release of alliance’s net liabilities
obligations due medicare
purchases of short-term investments
proceeds from sales of short-term investments
withdrawals from restricted cash
net (decrease) in cash and cash equivalents
proceeds from swingline facility
repayments of swingline facility
minority interests
impairment of intangible assets
release of shares from escrow
deposits into restricted cash
purchase of deferred compensation plan assets
proceeds from equity offering
issuance cost related to equity offering
proceeds from short-term revolving line of credit
principal payments of short-term revolving line of credit
repayments from swingline facility
cash paid for 2005 payroll taxes under hurricane relief act extended deadlines
non-cash compensation expense		128,000
401(k) employer match expense
proceeds from sales and maturities of short-term investments
sale of deferred compensation plan assets
changes in assets and liabilities, net of impact of acquisitions:
(increase) in patient accounts receivable
increase in other current assets
increase in other assets							-1,028,530	-470	-125
(decrease) in accounts payable												-719
increase in accrued expenses	-10,168,000	7,951,000	5,124,000	7,913,000	1,311,000	-1,214,000	6,985,386	1,614	-3	1,340	1,240	848
increase in other long-term obligations
(decrease) in obligations due medicare
issuance costs related to issuance of long-term debt
increase in patient accounts receivable
decrease in other assets
write-off of deferred debt issuance costs
write-off of medical supplies
changes in assets and liabilities, net of impact of acquisitions
decrease (increase) in other current assets
decrease (increase) in other assets											11	20
increase in accounts payable	19,752,000			-2,262,000	3,007,000			1,670
sale of short-term investments
proceeds from issuance of long-term obligations, net of issuance cost
other
stock issued for acquisitions			0	1,500,000	0
equity in earnings/(losses) of unconsolidated joint ventures
alliance
decrease in other current assets
benefit from bad debts	1,144,000	2,175,000	1,126,000	648,000	527,000	909,000	1,618,257	743	658	583	504	494
decrease (increase) in patient accounts receivable
(decrease) in other long-term obligations
(increase) in other current assets
(decrease) in medicare liabilities												-902
acquisitions of businesses
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
supplemental disclosures of non cash financing and investing activities:
stock issued for 401(k) plan
amortization of deferred debt issue costs
write off of inventory
changes in assets and liabilities, net of acquisitions:
(increase) in accounts receivable		-10,036,000	-13,272,000	-1,018,000
proceeds for sales and maturities of short–term investments
changes in assets and liabilities:
(increase) in other assets		1,753,000	-1,243,000	-2,363,000
other increases
cash paid for payroll taxes under hurricane relief act extended deadlines
compensation expense due to issuance of stock and stock options
loss on disposals of property and equipment	-22,000	-16,000	15,000	38,000
increase in inventory and other current assets					-405,000	-375,000
increase in amounts due to medicare
acquisition of businesses
proceeds from issuance of long-term debt
proceeds from equity offering, net of costs
principal payments of long-term debt
principal payments of revolving line of credit
payments on notes payable and capital leases			-648,000	-820,000		-1,144,000	-3,260,227	-1,773	-1,780	-1,658	-1,772	-1,700
proceeds from private placement of stock								-23
decrease in medicare liabilities										272
cash paid for income taxes
writeoff of inventory		0
(increase) in inventory and other current assets		502,000	-481,000	-1,588,000				-719				-564
(decrease) in long-term liabilities
purchase of property and equipment		-3,747,000	-6,173,000	-5,518,000	-1,661,000	-1,686,000	-1,883,375	-625	-1,044	-122	-325	-298
cash from purchase acquisitions		-121,571,000	-3,925,000	-15,743,000		-4,595,000	-20,727,849	-14,151
proceeds from issuance of long-term debt, net of issuance cost
payments on long-term debt and capital leases
proceeds from 2004 secondary equity offering, net of offering costs
supplemental disclosures of cash flow information
interest paid		425,000
income taxes paid, net of refunds received		25,000
non-cash financing activities:
stock issued as contributions to the company’s 401(k) plan		1,043,000	943,000	729,000		528,000
stock issued to sellers in acquisitions
notes payable issued to sellers in acquisitions
capital leases entered into
decrease in accounts payable										381
proceeds from issuance of notes payable					0	455,000	416,583	417
costs associated with equity offerings			0	-21,000
financing activities:
compensation expense				69,000		5,000	25,980	20
increase in medicare liabilities				-64,000				4
proceeds from issuance of stock from employee stock purchase plan				291,000		222,000	349,847	153		151
cash paid for:
interest				68,000	87,000	72,000	193,891	109	254	276	296	340
income taxes, net of refunds received				1,546,000
supplemental disclosures of noncash financing and investing activities
changes in assets and liabilities, net of impact of acquisitions—
partnership distributions
net (payments) on line of credit agreements
payments on notes payable
decrease in long-term liabilities
proceeds from other issuance of stock
proceeds from employee stock purchase plan
income taxes					348,000	1,576,000	805,700	300	128	56	116	-151
supplemental disclosures of non cash financing and investing activities
increase in accounts receivable						668,000	-6,275,549	-451
increase in long-term liabilities									-1
cash paid (received) for:
expenses incurred from 2003 private placement of stock
depreciation								894
deferred revenue
gain on sale of discontinued operations
minority interest
increase in cash included in assets held for sale
proceeds from sale of discontinued operations
minority interest investment in subsidiary
net (payments) borrowings on line of credit agreements
proceeds from issuance of notes payable and capital leases									91	472	135	544
proceeds from issuance of stock
decrease in notes payable—related parties
increase in notes receivable—related parties
decrease in accounts receivable										-2,726	934	2,746
decrease (increase) in inventory and other current assets										39
net repayments on line of credit agreements
cash paid for
net (repayments) on line of credit agreements
impairment of goodwill
changes in assets and liabilities—
issuance of warrants for extinguishment of debt
decrease in notes payable — related parties
increase in notes receivable — related parties

We provide you with 20 years of cash flow statements for Amedisys stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Amedisys stock. Explore the full financial landscape of Amedisys stock with our expertly curated income statements.

The information provided in this report about Amedisys stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.